Categories: News

Financière de Tubize – 2023 half-year financial report

Press release
29 July 2023

FINANCIERE DE TUBIZE SA

Allée de la Recherche 60, 1070 Brussels

Contact: Eric Nys, day-to-day management, eric.nys@financiere-tubize.be

2023 half-year financial report

Regulated information
29 July 2023

The board of directors of Financière de Tubize has issued the 2023 half-year financial report. This report is available on the website www.financiere-tubize.be

  • Profit for first half of 2023: € 91.1 million at 30 June 2023 (€ 87.3 million at 30 June 2022 (increase of 4.4%),
  • Dividend received from UCB: € 93.2 million (€ 1.33 per share, an increase of 2.3% compared to the previous year),
  • 2022 Dividend paid to Financière de Tubize’s shareholders in 2023 of € 38.3 million (€ 0.86 per share, an increase of  14.7% compared to the previous year),      
  • Acquisition, in 2023, of 649,750 UCB shares, for a total amount of € 52.0 million, at an average price of € 79.96, increasing the holding of the Company in UCB from 35.70% at 31 December 2022 to 36.04% at 30 June 2023.

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

6 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

7 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

7 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

8 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

10 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

10 hours ago